Collegium Pharmaceutical, Inc. (COLL) Reaches $21.23 After 6.00% Up Move; Shorts at Regeneron Pharmaceutical (REGN) Lowered By 1.37%

January 16, 2018 - By Darrin Black

Regeneron Pharmaceutical Incorporated (NASDAQ:REGN) had a decrease of 1.37% in short interest. REGN’s SI was 2.10M shares in January as released by FINRA. Its down 1.37% from 2.13 million shares previously. With 1.03 million avg volume, 2 days are for Regeneron Pharmaceutical Incorporated (NASDAQ:REGN)’s short sellers to cover REGN’s short positions. The SI to Regeneron Pharmaceutical Incorporated’s float is 2.7%. The stock increased 1.41% or $5.19 during the last trading session, reaching $372.15. About 474,764 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since January 16, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a huge mover today! The stock increased 6.04% or $1.21 during the last trading session, reaching $21.23. About 303,537 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has declined 44.24% since January 16, 2017 and is downtrending. It has underperformed by 60.94% the S&P500.The move comes after 6 months positive chart setup for the $691.30M company. It was reported on Jan, 16 by Barchart.com. We have $22.50 PT which if reached, will make NASDAQ:COLL worth $41.48M more.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It dropped, as 56 investors sold Regeneron Pharmaceuticals, Inc. shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. California State Teachers Retirement Sys invested in 131,173 shares or 0.13% of the stock. Gamco Et Al holds 0% or 482 shares. Sterling Capital Management Ltd Llc has 0.06% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 13,733 shares. Kbc Gp Nv holds 0.04% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 8,816 shares. Exxonmobil Invest Mgmt Tx, a Texas-based fund reported 14,030 shares. National Bank & Trust Of Nova Scotia, a Ontario – Canada-based fund reported 13,344 shares. Oppenheimer Company Inc stated it has 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Natixis reported 20,379 shares. Cornerstone Advsrs accumulated 0.26% or 5,000 shares. California-based Capital World has invested 0.67% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Panagora Asset Management reported 67,677 shares. Mitsubishi Ufj Trust And Bk stated it has 0.13% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Boston Private Wealth Ltd Liability reported 907 shares. Bridgewater Associate Limited Partnership holds 0.08% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 25,700 shares. San Francisco Sentry Investment Gp (Ca) holds 0.2% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 1,329 shares.

Since August 7, 2017, it had 2 insider purchases, and 8 selling transactions for $78.43 million activity. VAGELOS P ROY also sold $26.67 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. 427 shares were sold by Landry Robert E, worth $210,693 on Wednesday, August 30. Shares for $712,500 were sold by BROWN MICHAEL S. 72,378 shares were bought by Sanofi, worth $34.84 million on Friday, August 25. The insider BAKER CHARLES A sold 2,000 shares worth $900,000.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $39.78 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 33.75 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Among 31 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 17 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. had 104 analyst reports since July 28, 2015 according to SRatingsIntel. On Friday, December 16 the stock rating was upgraded by BTIG Research to “Buy”. The company was maintained on Thursday, November 9 by BMO Capital Markets. The firm earned “Buy” rating on Monday, August 31 by RBC Capital Markets. The rating was maintained by Barclays Capital on Wednesday, August 5 with “Equal Weight”. Bernstein downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, June 26 to “Market Perform” rating. As per Tuesday, January 9, the company rating was upgraded by Citigroup. The rating was maintained by Piper Jaffray with “Buy” on Friday, July 21. J.P. Morgan maintained the shares of REGN in report on Thursday, August 3 with “Hold” rating. The stock has “Buy” rating by UBS on Friday, August 4. The rating was maintained by BMO Capital Markets on Monday, September 11 with “Hold”.

Analysts await Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings on March, 8. They expect $-0.55 earnings per share, up 46.08% or $0.47 from last year’s $-1.02 per share. After $-0.45 actual earnings per share reported by Collegium Pharmaceutical, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $691.30 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.